These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 26222073)

  • 21. Ganglioside GM3 inhibits VEGF/VEGFR-2-mediated angiogenesis: direct interaction of GM3 with VEGFR-2.
    Chung TW; Kim SJ; Choi HJ; Kim KJ; Kim MJ; Kim SH; Lee HJ; Ko JH; Lee YC; Suzuki A; Kim CH
    Glycobiology; 2009 Mar; 19(3):229-39. PubMed ID: 18974200
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Imaging tumor angiogenesis.
    Red-Horse K; Ferrara N
    J Clin Invest; 2006 Oct; 116(10):2585-7. PubMed ID: 17016553
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pathogenesis of ascites tumor growth: angiogenesis, vascular remodeling, and stroma formation in the peritoneal lining.
    Nagy JA; Morgan ES; Herzberg KT; Manseau EJ; Dvorak AM; Dvorak HF
    Cancer Res; 1995 Jan; 55(2):376-85. PubMed ID: 7529135
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [VEGF and its receptors as therapeutic target in cancer therapy].
    Gisterek I; Kornafel J
    Przegl Lek; 2006; 63(3):155-7. PubMed ID: 16967703
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Vascular endothelial growth factor receptors: expression and function in solid tumors.
    Wey JS; Stoeltzing O; Ellis LM
    Clin Adv Hematol Oncol; 2004 Jan; 2(1):37-45. PubMed ID: 16163158
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antiangiogenesis and vascular endothelial growth factor/vascular endothelial growth factor receptor targeting as part of a combined-modality approach to the treatment of cancer.
    O'Reilly MS
    Int J Radiat Oncol Biol Phys; 2007; 69(2 Suppl):S64-6. PubMed ID: 17848299
    [No Abstract]   [Full Text] [Related]  

  • 27. [VEGF, anti-vEGF and diseases].
    Corvol P
    Bull Acad Natl Med; 2008 Feb; 192(2):289-300; discussion 300-2. PubMed ID: 18819684
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Blocking angiogenesis and tumorigenesis with GFA-116, a synthetic molecule that inhibits binding of vascular endothelial growth factor to its receptor.
    Sun J; Blaskovich MA; Jain RK; Delarue F; Paris D; Brem S; Wotoczek-Obadia M; Lin Q; Coppola D; Choi K; Mullan M; Hamilton AD; Sebti SM
    Cancer Res; 2004 May; 64(10):3586-92. PubMed ID: 15150116
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tumors: Wounds That Do Not Heal-A Historical Perspective with a Focus on the Fundamental Roles of Increased Vascular Permeability and Clotting.
    Dvorak HF
    Semin Thromb Hemost; 2019 Sep; 45(6):576-592. PubMed ID: 31096305
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis.
    Hicklin DJ; Ellis LM
    J Clin Oncol; 2005 Feb; 23(5):1011-27. PubMed ID: 15585754
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Anti-angiogenic therapy against gastrointestinal tract cancers.
    Iwasaki J; Nihira S
    Jpn J Clin Oncol; 2009 Sep; 39(9):543-51. PubMed ID: 19531544
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Vessel abnormalization: another hallmark of cancer? Molecular mechanisms and therapeutic implications.
    De Bock K; Cauwenberghs S; Carmeliet P
    Curr Opin Genet Dev; 2011 Feb; 21(1):73-9. PubMed ID: 21106363
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Current insights on the biology and clinical aspects of VEGF regulation.
    Birk DM; Barbato J; Mureebe L; Chaer RA
    Vasc Endovascular Surg; 2008 Dec-2009 Jan; 42(6):517-30. PubMed ID: 18799497
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Angiogenesis inhibitors: a rational strategy for radiosensitization in the treatment of non-small-cell lung cancer?
    Raben D; Helfrich B
    Clin Lung Cancer; 2004 Jul; 6(1):48-57. PubMed ID: 15310417
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of vascular normalization by antiangiogenic therapy on interstitial hypertension, peritumor edema, and lymphatic metastasis: insights from a mathematical model.
    Jain RK; Tong RT; Munn LL
    Cancer Res; 2007 Mar; 67(6):2729-35. PubMed ID: 17363594
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The multifaceted activity of VEGF in angiogenesis - Implications for therapy responses.
    Moens S; Goveia J; Stapor PC; Cantelmo AR; Carmeliet P
    Cytokine Growth Factor Rev; 2014 Aug; 25(4):473-82. PubMed ID: 25169850
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Anti-angiogenesis targeting drugs: a review].
    Jia K; Li J
    Ai Zheng; 2008 Apr; 27(4):442-6. PubMed ID: 18423135
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Angiogenesis and hypertension: the dual role of anti-hypertensive and anti-angiogenic therapies.
    Ferroni P; Della-Morte D; Palmirotta R; Rundek T; Guadagni F; Roselli M
    Curr Vasc Pharmacol; 2012 Jul; 10(4):479-93. PubMed ID: 22272903
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Structure and function of vascular endothelial growth factor and its receptor system.
    Park SA; Jeong MS; Ha KT; Jang SB
    BMB Rep; 2018 Feb; 51(2):73-78. PubMed ID: 29397867
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Brain angiogenesis in developmental and pathological processes: therapeutic aspects of vascular endothelial growth factor.
    Shibuya M
    FEBS J; 2009 Sep; 276(17):4636-43. PubMed ID: 19664071
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.